Heartflow Soars on Raised Revenue Outlook

Heartflow's stock experienced a notable increase on Friday following an upward revision of its full-year revenue projections. The medical diagnostics company now anticipates 2026 revenue to grow between 40%-42%, reaching $246 million to $250 million, a significant increase from its previous forecast of 29%-32% growth.

This positive outlook is supported by strong second-quarter results, with revenue climbing 48% year over year to $64.1 million. Furthermore, Heartflow's adjusted gross margin improved to 83.3% from 75.6% in the prior year's comparable period. The company’s adjusted operating loss also narrowed.

Heartflow utilizes cutting-edge AI in its Heartflow One platform to create personalized 3D heart models, aiding doctors in diagnosing coronary artery disease non-invasively. Management has also lifted its adjusted gross margin target to 82% from 81%, citing increasing scalability and confidence in long-term profitable growth.